{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T08:33:51Z","timestamp":1787906031677,"version":"build-2784847793"},"reference-count":9,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","jpurol.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pediatric Urology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jpurol.2024.12.003","type":"journal-article","created":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T05:50:05Z","timestamp":1736056205000},"page":"303-309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Long-term efficacy of Mirabegron-anticholinergic combination in paediatric neurogenic bladder"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0370-6917","authenticated-orcid":false,"given":"Arash K.","family":"Taghizadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Clothier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6721-1423","authenticated-orcid":false,"given":"Anna","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Manuele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpurol.2024.12.003_bib1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/nau.24211","article-title":"EAU\/ESPU guidelines on the management of neurogenic bladder in children and adolescent part I diagnostics and conservative treatment","volume":"39","author":"Stein","year":"2020","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.jpurol.2024.12.003_bib2","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1007\/s00345-018-2576-0","article-title":"Efficacy and safety of mirabegron, a \u03b23-adrenoceptor agonist, for treating neurogenic bladder in pediatric patients with spina bifida: a retrospective pilot study","volume":"37","author":"Park","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.jpurol.2024.12.003_bib3","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/nau.23566","article-title":"Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity-Prospective, randomized, double-blind, placebo-controlled study","volume":"37","author":"Krhut","year":"2018","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.jpurol.2024.12.003_bib4","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/nau.24928","article-title":"The efficacy and safety of mirabegron for adult and child patients with neurogenic lower urinary tract dysfunction: a systematic review and meta-analysis","volume":"41","author":"Yuanzhuo","year":"2022","journal-title":"Neurourol Urodyn"},{"issue":"31","key":"10.1016\/j.jpurol.2024.12.003_bib5","article-title":"The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation","volume":"16","author":"Rittig","year":"2020","journal-title":"J Pediatr Urol"},{"key":"10.1016\/j.jpurol.2024.12.003_bib6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s40272-021-00452-4","article-title":"Mirabegron: pediatric first approval","volume":"23","author":"Keam","year":"2021","journal-title":"Pediatr Drugs"},{"key":"10.1016\/j.jpurol.2024.12.003_bib7","doi-asserted-by":"crossref","first-page":"655.e1","DOI":"10.1016\/j.jpurol.2020.07.020","article-title":"Efficacy and safety of Mirabegron as adjuvant treatment in children with refractory neurogenic bladder dysfunction","volume":"16","author":"Sager","year":"2020","journal-title":"J Pediatr Urol"},{"key":"10.1016\/j.jpurol.2024.12.003_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpurol.2023.08.015","article-title":"Long-term beneficial effects of mirabegron in pediatric patients with therapy-refractory neurogenic lower urinary tract dysfunction","author":"van Veen","year":"2023","journal-title":"J Pediatr Urol"},{"key":"10.1016\/j.jpurol.2024.12.003_bib9","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.juro.2014.01.110","article-title":"The standardization of terminology of lower urinary tract function in children and adolescents: update report from the Standardization Committee of the International Children's Continence Society","volume":"191","author":"Austin","year":"2014","journal-title":"J Urol"}],"container-title":["Journal of Pediatric Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147751312400620X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147751312400620X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T02:56:17Z","timestamp":1741920977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147751312400620X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S147751312400620X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpurol.2024.12.003","relation":{},"ISSN":["1477-5131"],"issn-type":[{"value":"1477-5131","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term efficacy of Mirabegron-anticholinergic combination in paediatric neurogenic bladder","name":"articletitle","label":"Article Title"},{"value":"Journal of Pediatric Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpurol.2024.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2024 Published by Elsevier Ltd on behalf of Journal of Pediatric Urology Company. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}